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 Case Report 
 A 62-year-old woman was admitted to our hospital with acute 
onset of left-sided hemiparesis. On admission, she had left-sided 
hemiplegia and facial palsy with minor dysarthria – National Insti-
tutes of Health Stroke Scale (NIHSS) 11. Cerebral computed to-
mography (CCT) and CT angiography demonstrated right MCA 
mainstem occlusion but no early ischemic changes. We initiated 
thrombolysis with rt-PA (0.9 mg/kg) 165 min after symptom onset. 
With this therapy, the patient improved to NIHSS 5. 
 However, 1 h after termination of thrombolysis, she developed 
a sudden decline of consciousness. Since a repeat CCT ruled out 
intracranial hemorrhage (ICH), we suspected non-convulsive sta-
tus epilepticus and gave intravenous lorazepam (6 mg) and val-
proic acid (bolus administration 900 mg, followed by 6-hour infu-
sion 100 mg    h –1 ). Electroencephalographic (EEG) monitoring was 
technically not feasible. The patient remained stuporous requiring 
intubation and mechanical ventilation the next morning. MRI 
demonstrated a new occlusion of the left MCA and the left internal 
carotid artery (ICA), as confi rmed by duplex ultrasound. The right 
MCA appeared recanalized ( fi g. 1 ). In the presence of only small 
DWI lesions, PI showed a perfusion defi cit of the complete left 
MCA territory resulting in a large PI/DWI mismatch. Therefore, 
we initiated treatment with intravenous abciximab (bolus admin-
istration 0.25 mg/kg, followed by 12-hour infusion therapy 
0.125   g    kg –1     min –1 ) 17.5 h after onset of new symptoms.  
 Duplex sonography performed after the abciximab infusion 
demonstrated persistent occlusion of the left ICA but recanaliza-
tion of the left MCA. The patient initially remained comatous. 
Repeated CCTs on days 1, 3 and 5 after thrombolysis ruled out 
ICH or major ischemia. EEG ruled out seizure activity, and there 
was no evidence for metabolic coma. She subsequently regained 
consciousness and was extubated after 11 days. 
 Further workup revealed a stalked thrombus in the left atrial 
ear (transesophageal echocardiography) and intermittent atrial fi -
 Introduction 
 Intravenous thrombolysis with alteplase (rt-PA) is the treatment 
of choice for ischemic stroke within 3 h of symptom onset  [1] . Meta-
analysis of the major thrombolytic stroke trials suggest a small, but 
still signifi cant, benefi t if given within 3–6 h  [2–4] . Based on the 
results of a recent trial, the glycoprotein IIb/IIIa receptor antagonist 
abciximab may be a treatment option for this time window  [5] . 
 Potentially viable penumbral tissue may be present well beyond 
6 h, in isolated cases even up to 48 h  [6] . Modern imaging tech-
niques like magnetic resonance imaging (MRI) using diffusion-
weighted (DWI) and perfusion imaging (PI) may identify the pen-
umbra and permit improved patient selection  [7, 8] . Nevertheless, 
the best treatment for these patients has not yet been defi ned. This 
particularly applies to patients with recurrent or new symptoms 
after an initially successful thrombolysis where an early second 
thrombolytic therapy is debatable. 
 We report on a patient with acute left middle cerebral artery 
(MCA) occlusion occurring after thrombolysis with rt-PA for right 
MCA occlusion, whom we successfully treated with intravenous 
abciximab 17.5 h after onset of new symptoms. 
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 Fig. 1. MRI was performed 16.5 h after 
clinical deterioration: MR angiography 
demonstrates new occlusions of the left 
MCA and ICA while the right MCA is re-
canalized ( a ). DWI shows bilateral ischemic 
lesions in the basal ganglia and left insular 
ribbon ( b ). PI demonstrates a perfusion def-
icit of the complete left MCA territory re-
sulting in a PI/DWI mismatch ( c ). 
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brillation (Holter ECG) strongly suggesting recurrent cardiac em-
bolism. Therefore, we commenced secondary prophylaxis with sub-
cutaneous low-molecular-weight heparin (nadroparin 0.7 ml/day) 
2 days after thrombolysis with abciximab. An asymptomatic left 
temporo-occipital ICH seen on routine MRI 3 weeks after throm-
bolysis was rated as a complication of anticoagulation but did not 
result in therapeutic alterations. 
 Two months later, we saw the patient in our outpatient clinic. 
She had a minor right-sided hemiparesis and was independent 
without help (NIHSS 2, modifi ed Rankin Scale 1). The fi nal infarc-
tion volume corresponded to the DWI lesions on the initial MRI. 
The ICH had resolved completely ( fi g. 2 ). Subsequently, the patient 
was started on warfarin. 
 Discussion 
 In acute ischemic stroke, the identifi cation of an ischemic pen-
umbra may result in a therapeutic dilemma, because treatment 
beyond 6 h after symptom onset has only been studied in a phase 
II study so far  [9] . Nevertheless, the penumbra may be present for 
up to 48 h  [4] , and consequently, thrombolytic therapy may be jus-
tifi ed. 
 The glycoprotein IIb/IIIa receptor anatagonist abciximab has 
been safely applied up to 24 h after the onset of ischemic stroke 
 [10] . So far, abciximab has not proven its effi cacy, but showed a 
nonsignifi cant shift in favorable functional outcomes as measured 
by the modifi ed Rankin Scale score at 3 months (odds ratio 1.20; 
p = 0.33; 95% CI 0.84–1.70)  [5] . Therefore, abciximab is expected 
to play a major role in future stroke therapy  [11] . 
 In this case report, abciximab was applied 17.5 h after the onset 
of new symptoms following fi brinolysis with rt-PA for right-sided 
MCA occlusion. The long time lag until a diagnosis of recurrent 
stroke was reached was caused by initial misinterpretation of symp-
toms. Non-convulsive status epilepticus at stroke onset may have 
contributed to the clinical deterioration, but was not proven be-
cause EEG monitoring was technically not feasible. Several EEGs 
performed in the postacute phase showed no epileptic activity. 
Nevertheless, seizure at stroke onset should not be regarded as an 
absolute contraindication to thrombolysis in the presence of poten-
tially salvageable tissue  [12] . 
 The demonstration of left MCA occlusion and PI/DWI mis-
match proved that recurrent stroke was the main reason for the 
secondary clinical deterioration of the patient. This situation was 
presumably caused by recurrent cardiac embolism. Few case re-
ports outline the risk of rt-PA in the setting of myocardial infarction 
or ischemic stroke to break up or detach cardiac thrombotic mate-
rial and promote recurrent embolism  [13, 14] . This mechanism 
might also have been relevant in our patient. However, in a recent 
series of 5 stroke patients with a cardiac thrombus undergoing 
thrombolysis with rt-PA, there was no increased risk of recurrent 
embolism  [15] . 
 Despite the prolonged time window and prior rt-PA treatment, 
therapy with abciximab was safe, because no ICH occurred. The 
ICH seen on MRI 3 weeks after thrombolysis was related to anti-
coagulation with low-molecular-weight heparin because it did not 
show on prior CCTs. Abciximab was also effective because the fi nal 
infarction volume corresponded to the initial DWI lesion, the oc-
cluded MCA was recanalized early, and the patient had a good 
clinical outcome. 
 In conclusion, therapy with abciximab can be a treatment op-
tion in selected patients even if given beyond 6 h after symptom 
onset and after prior thrombolysis with rt-PA. 
 Fig. 2. Repeat CCT performed 2 months after thrombolytic thera-
py shows infarctions in the basal ganglia bilaterally, in the left in-
sular ribbon and the internal capsule, identical to the DWI lesions 
on initial MRI. The asymptomatic left temporo-occipital ICH seen 
on routine MRI 3 weeks after thrombolysis is completely re-
sorbed. 
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 Limb-Shaking Transient Ischemic Attack 
Induced by Middle Cerebral Artery Stenosis  
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Yong-Jun Wang a  
  a   Neurovascular Angioplasty Team, Department of Neurology 
and Neuroradiology, Beijing Tiantan Hospital, Capital 
University of Medical Sciences,  Beijing , China, and  b   All India 
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A 71-year-old female presented with a 3-month history of epi-
sodic shaking movements of the left leg. She had a history of hy-
pertension for the past 10 years. These recurrent episodes would 
usually begin with a sensation of ‘weakness’ involving predomi-
nantly her left leg, and at times, the left arm. This was followed by 
the involuntary, focal, arrhythmic shaking movements of her left 
leg for about 30–45 s without spread to other limbs or body parts. 
The whole event would last for less than 5 min. Her consciousness 
was not impaired during the attacks. These attacks would occur 
during prolonged standing and walking. There were 4–5 attacks per 
day with increased frequency in the last month. The general phys-
ical and neurological examinations were normal. Her blood pres-
sure was 155/70 mm Hg and there was no orthostatic hypotension. 
The ambulatory electroencephalographic monitoring was normal. 
Diffusion-weighted MRI revealed hyperintense lesions in the right 
border zone between the anterior cerebral artery (ACA) and middle 
cerebral artery (MCA) ( fi g. 1 a). Magnetic resonance angiogram 
showed severe focal stenosis of the right MCA and absence of bi-
lateral ACA ( fi g. 1 b). Perfusion CT showed delayed time to peak 
and mean transit time, increased relative cerebral blood fl ow, and 
slightly decreased relative cerebral blood fl ow in right anterior fron-
tal lobe, the right anterior and posterior border zone and the right 
basal ganglia ( fi g. 1 c). Digital substraction angiography showed se-
vere focal stenosis of the M1 segment of the right MCA and absence 
of bilateral ACA. The right border zone (between ACA and MCA) 
was shifted internally, suggestive of the right ACA territory being 
compensated partially by the leptomeningeal collateral vessels from 
the right MCA ( fi g. 1 d). Extracranial segment of the right internal 
carotid artery was normal. The patient was diagnosed as a case of 
 Fig. 1.  a Diffusion-weighted MRI revealed high signal intensity le-
sions in the right watershed territory between the ACA and MCA. 
 b Magnetic resonance angiogram showed severe focal stenosis of 
the right MCA and absence of bilateral ACA.  c Perfusion CT 
showed delayed mean transit time in the right anterior frontal lobe, 
the right anterior and posterior border zone, and the right basal 
ganglia.  d Digital substraction angiography showed severe focal 
stenosis of the M1 segment of the right MCA and absence of the 
ACA. The right border zone (between the ACA and MCA) shifted 
internally, suggestive of the right ACA territory being compensated 
partially by the leptomeningeal collateral vessels from the right 
MCA. 
